IL310203A - Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide - Google Patents

Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide

Info

Publication number
IL310203A
IL310203A IL310203A IL31020324A IL310203A IL 310203 A IL310203 A IL 310203A IL 310203 A IL310203 A IL 310203A IL 31020324 A IL31020324 A IL 31020324A IL 310203 A IL310203 A IL 310203A
Authority
IL
Israel
Prior art keywords
solid preparation
compound
mannitol
tablet
npl
Prior art date
Application number
IL310203A
Other languages
English (en)
Hebrew (he)
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59014064&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL310203(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of IL310203A publication Critical patent/IL310203A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL310203A 2015-12-02 2016-12-01 Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide IL310203A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015236034 2015-12-02
PCT/JP2016/085822 WO2017098998A1 (fr) 2015-12-02 2016-12-01 Composition pharmaceutique contenant de la 2-{4-[n-(5,6-diphénylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(méthylsulfonyl)acétamide

Publications (1)

Publication Number Publication Date
IL310203A true IL310203A (en) 2024-03-01

Family

ID=59014064

Family Applications (3)

Application Number Title Priority Date Filing Date
IL310203A IL310203A (en) 2015-12-02 2016-12-01 Pharmaceutical composition containing 2-{4n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n- (methylsulfonyl)acetamide
IL330192A IL330192A (en) 2015-12-02 2016-12-01 Pharmaceutical preparation containing 2-{4-[N-(6,5-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
IL259461A IL259461A (en) 2015-12-02 2018-05-17 Pharmaceutical preparation containing 2-{4-[n-(6,5-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide

Family Applications After (2)

Application Number Title Priority Date Filing Date
IL330192A IL330192A (en) 2015-12-02 2016-12-01 Pharmaceutical preparation containing 2-{4-[N-(6,5-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide
IL259461A IL259461A (en) 2015-12-02 2018-05-17 Pharmaceutical preparation containing 2-{4-[n-(6,5-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide

Country Status (32)

Country Link
US (2) US10821108B2 (fr)
EP (3) EP4331607B1 (fr)
JP (1) JP6825574B2 (fr)
KR (1) KR102759845B1 (fr)
CN (1) CN108289890B (fr)
AU (1) AU2016366073B2 (fr)
BR (1) BR112018009534B1 (fr)
CL (1) CL2018001464A1 (fr)
CO (1) CO2018006834A2 (fr)
DK (1) DK4331607T3 (fr)
EC (1) ECSP18049108A (fr)
ES (1) ES3030325T3 (fr)
FI (1) FI4331607T3 (fr)
HR (1) HRP20250572T1 (fr)
HU (1) HUE071411T2 (fr)
IL (3) IL310203A (fr)
LT (1) LT4331607T (fr)
MX (1) MX385595B (fr)
MY (1) MY198164A (fr)
PE (1) PE20181072A1 (fr)
PH (1) PH12018501161B1 (fr)
PL (1) PL4331607T3 (fr)
PT (1) PT4331607T (fr)
RS (1) RS66791B1 (fr)
RU (1) RU2735547C2 (fr)
SA (1) SA518391686B1 (fr)
SG (1) SG11201804320QA (fr)
SI (1) SI4331607T1 (fr)
TW (1) TWI750143B (fr)
UA (1) UA124002C2 (fr)
WO (1) WO2017098998A1 (fr)
ZA (1) ZA201804387B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190204A1 (ar) 2017-03-08 2019-09-05 Actelion Pharmaceuticals Ltd تركيبة صيدلانية تشتمل على سيليكسيباغ
AR113882A1 (es) * 2017-11-16 2020-06-24 Nippon Shinyaku Co Ltd Preparación de liberación controlada
AR114399A1 (es) * 2018-02-21 2020-09-02 Nippon Shinyaku Co Ltd Composición granular, método de producción para composición granular y método de mejora de la propiedad de disolución para composición granular
WO2020157730A1 (fr) 2019-02-03 2020-08-06 Patel Jayendrakumar Dasharathlal Composition pharmaceutique à libération contrôlée de sélexipag ou son métabolite actif
US20210069187A1 (en) * 2019-05-11 2021-03-11 RK Pharma Solutions LLC Stable pharmaceutical composition of Selexipag
JP7646646B2 (ja) * 2019-10-23 2025-03-17 日本新薬株式会社 セレキシパグを含む医薬組成物
JP7628504B2 (ja) 2019-11-25 2025-02-10 エセックス・ソリューションズ・ジャパン株式会社 絶縁電線、コイル、及び電気・電子機器
JP6989064B1 (ja) * 2020-04-10 2022-01-05 日本新薬株式会社 固形製剤及びその製造方法
CN112220770B (zh) * 2020-12-17 2021-04-09 上海翰森生物医药科技有限公司 司来帕格的药物组合物及其制备方法
WO2022240378A1 (fr) * 2021-05-11 2022-11-17 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Composition pharmaceutique stable comprenant du sélexipag

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3145431B2 (ja) 1991-08-20 2001-03-12 日本酸素株式会社 安定同位体標識蛋白質の製造法および試薬キット
US20010001106A1 (en) 1996-04-16 2001-05-10 Tomohiro Yoshinari D-mannitol and its preparation
JP3126683B2 (ja) 1996-04-16 2001-01-22 武田薬品工業株式会社 Ｄ−マンニトールおよびその製造法
EP1282416A2 (fr) 2000-05-19 2003-02-12 Progenics Pharmaceuticals, Inc. Formulations d'acide dehydroascorbique et leurs utilisations
DK1178047T3 (da) 2000-08-03 2004-05-24 Pfizer Prod Inc Diazabicyclooctanderivater og terapeutiske anvendelser deraf
TWI316055B (fr) * 2001-04-26 2009-10-21 Nippon Shinyaku Co Ltd
EP1551401A4 (fr) 2002-09-20 2006-03-22 Merck & Co Inc Formulation de mannitol destinee a un antagoniste de recepteur d'integrine
JP2004269513A (ja) 2003-02-19 2004-09-30 Rohto Pharmaceut Co Ltd 固形製剤
US7112393B2 (en) 2003-07-29 2006-09-26 Canon Kabushiki Kaisha Non-magnetic toner
BRPI0810978B1 (pt) 2007-05-28 2021-05-25 Mitsubishi Shoji Foodtech Co., Ltd Partícula esférica de manitol cristalino
FR2918566B1 (fr) 2007-07-11 2009-10-09 Pierre Fabre Medicament Sa Composition pharmaceutique stable d'un sel hydrosoluble de vinflunine.
KR20100099113A (ko) 2007-10-12 2010-09-10 아스트라제네카 아베 만니톨 및/또는 미세결정질 셀룰로스를 포함하는 지보텐탄 조성물
US20110053942A1 (en) 2008-02-13 2011-03-03 Dainippon Sumitomo Pharma Co., Ltd. Orally disintegrating tablets
EP2246336B1 (fr) 2008-02-28 2020-07-01 Nippon Shinyaku Co., Ltd. Inhibiteur de fibrose
WO2009154246A1 (fr) 2008-06-19 2009-12-23 日本新薬株式会社 Agent thérapeutique pour un dysfonctionnement érectile
HRP20151443T1 (hr) 2008-06-23 2016-01-29 Nippon Shinyaku Co., Ltd. Terapijsko sredstvo protiv stenoze kralježniäśnog kanala
SI2289518T1 (sl) 2008-06-23 2017-02-28 Nippon Shinyaku Co., Ltd. Terapevtsko sredstvo za vnetno črevesno bolezen
WO2009157397A1 (fr) 2008-06-23 2009-12-30 日本新薬株式会社 Agent thérapeutique pour une lésion au tractus intestinal accompagnant l’administration d’un anti-inflammatoire nonstéroïdien
SG176915A1 (en) 2009-06-26 2012-01-30 Nippon Shinyaku Co Ltd Crystals
ES2733998T3 (es) 2012-10-29 2019-12-03 Cardio Incorporated Agente terapéutico específico de enfermedad pulmonar
CN103690496B (zh) 2013-12-27 2015-04-01 哈药集团生物工程有限公司 一种含有奥扎格雷钠的冻干药物组合物

Also Published As

Publication number Publication date
US20180325895A1 (en) 2018-11-15
UA124002C2 (uk) 2021-07-07
PH12018501161A1 (en) 2019-01-21
RU2018123304A (ru) 2020-01-09
MX2018006343A (es) 2018-08-01
MX385595B (es) 2025-03-18
SI4331607T1 (sl) 2025-06-30
IL259461A (en) 2018-07-31
IL330192A (en) 2026-08-01
TWI750143B (zh) 2021-12-21
EP3384911A4 (fr) 2019-05-15
KR20180081141A (ko) 2018-07-13
JPWO2017098998A1 (ja) 2018-09-20
EP4501404A3 (fr) 2025-05-07
EP4331607B1 (fr) 2025-04-30
EP4331607A3 (fr) 2024-05-29
ZA201804387B (en) 2020-12-23
AU2016366073B2 (en) 2021-08-26
BR112018009534A2 (pt) 2018-11-06
RS66791B1 (sr) 2025-06-30
SA518391686B1 (ar) 2024-03-03
PE20181072A1 (es) 2018-07-04
FI4331607T3 (fi) 2025-06-03
WO2017098998A1 (fr) 2017-06-15
PH12018501161B1 (en) 2024-07-03
NZ742784A (en) 2024-08-30
RU2735547C2 (ru) 2020-11-03
US10828298B2 (en) 2020-11-10
SG11201804320QA (en) 2018-06-28
EP3384911A1 (fr) 2018-10-10
KR102759845B1 (ko) 2025-01-23
PL4331607T3 (pl) 2025-06-16
US10821108B2 (en) 2020-11-03
CL2018001464A1 (es) 2018-10-19
RU2018123304A3 (fr) 2020-04-02
TW201720444A (zh) 2017-06-16
ECSP18049108A (es) 2018-10-31
EP4501404A2 (fr) 2025-02-05
AU2016366073A1 (en) 2018-06-14
PT4331607T (pt) 2025-05-22
CN108289890B (zh) 2021-04-27
ES3030325T3 (en) 2025-06-27
DK4331607T3 (da) 2025-05-19
CA3005169A1 (fr) 2017-06-15
CN108289890A (zh) 2018-07-17
HUE071411T2 (hu) 2025-08-28
US20180333413A1 (en) 2018-11-22
JP6825574B2 (ja) 2021-02-03
HRP20250572T1 (hr) 2025-07-04
CO2018006834A2 (es) 2018-07-10
LT4331607T (lt) 2025-06-10
EP4331607A2 (fr) 2024-03-06
MY198164A (en) 2023-08-08
BR112018009534B1 (pt) 2023-11-07

Similar Documents

Publication Publication Date Title
US10828298B2 (en) Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy]-N-(methylsulfonyl)acetamide
JP6934932B2 (ja) アンドロゲン受容体アンタゴニストの固体医薬組成物
EP3711763A1 (fr) Formulation à libération contrôlée
JP2024169553A (ja) 固形製剤及びその製造方法
KR101469326B1 (ko) 베포타스틴 또는 이의 약학적으로 허용가능한 염과 수불용성 염기성 물질을 포함하는 약제학적 제제
AU2019225516A1 (en) Granular composition, production method for granular composition, and dissolution property improvement method for granular composition
CA3005169C (fr) Composition solide stabilisee contenant 2-{4-[n-(5,6-diphenylpyrazine-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyle)acetamide et d-mannitol
WO2015069203A1 (fr) Capsule comprenant du fumarate de rupatadine et du montélukast sodique
HK40115604A (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
HK40100555A (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
HK40100555B (en) Solid pharmaceutical composition containing 2-{4-[n-(5,6-diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy}-n-(methylsulfonyl)acetamide
WO2025164725A1 (fr) Composition pharmaceutique contenant un dérivé de dihydropyridone
HK40036074A (en) Controlled release formulation
EP3731823A1 (fr) Préparation pharmaceutique pour administration par voie orale comportant de l'étexilate de dabigatran
TW200808356A (en) Improved oral pharmaceutical composition of a poorly water-soluble active substance